ATE270661T1 - Verfahren zur herstellung von amorphem atorvastatin - Google Patents

Verfahren zur herstellung von amorphem atorvastatin

Info

Publication number
ATE270661T1
ATE270661T1 AT00977807T AT00977807T ATE270661T1 AT E270661 T1 ATE270661 T1 AT E270661T1 AT 00977807 T AT00977807 T AT 00977807T AT 00977807 T AT00977807 T AT 00977807T AT E270661 T1 ATE270661 T1 AT E270661T1
Authority
AT
Austria
Prior art keywords
atorvastatin
solvent
type
amorphous atorvastatin
producing amorphous
Prior art date
Application number
AT00977807T
Other languages
English (en)
Inventor
Zlatko Pflaum
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of ATE270661T1 publication Critical patent/ATE270661T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00977807T 1999-12-10 2000-12-05 Verfahren zur herstellung von amorphem atorvastatin ATE270661T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9900271A SI20425A (sl) 1999-12-10 1999-12-10 Priprava amorfnega atorvastatina
PCT/IB2000/001797 WO2001042209A1 (en) 1999-12-10 2000-12-05 Process for the preparation of amorphous atorvastatin

Publications (1)

Publication Number Publication Date
ATE270661T1 true ATE270661T1 (de) 2004-07-15

Family

ID=20432564

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977807T ATE270661T1 (de) 1999-12-10 2000-12-05 Verfahren zur herstellung von amorphem atorvastatin

Country Status (22)

Country Link
US (2) US6613916B2 (de)
EP (1) EP1237864B1 (de)
JP (1) JP5087193B2 (de)
KR (1) KR100729689B1 (de)
AT (1) ATE270661T1 (de)
AU (1) AU776854B2 (de)
BG (1) BG65719B1 (de)
CA (1) CA2392025C (de)
CZ (1) CZ301627B6 (de)
DE (1) DE60012045T2 (de)
EE (1) EE05328B1 (de)
ES (1) ES2223615T3 (de)
HR (1) HRP20020482B1 (de)
PL (1) PL208226B1 (de)
PT (1) PT1237864E (de)
RS (1) RS50307B (de)
RU (1) RU2247113C2 (de)
SI (1) SI20425A (de)
SK (1) SK287032B6 (de)
TR (1) TR200402543T4 (de)
UA (1) UA71041C2 (de)
WO (1) WO2001042209A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (de) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
BR0210666A (pt) 2001-06-29 2004-10-05 Warner Lambert Co Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
HUP0500074A3 (en) 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HU227041B1 (en) * 2003-03-24 2010-05-28 Richter Gedeon Nyrt Process for the synthesis of amorphous atorvastatin calcium
AU2004228607B2 (en) * 2003-04-11 2011-01-27 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
WO2005090301A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
WO2005092852A1 (en) * 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
CN101039906A (zh) * 2004-10-18 2007-09-19 特瓦制药工业有限公司 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048888A1 (en) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Novel process for the preparation of amorphous atorvastatin calcium salt
WO2006048893A2 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited A process for synthesis of large particle size statin compounds
ES2263370B1 (es) * 2005-02-16 2007-12-01 Ercros Industrial, S.A. Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
EP1905424A3 (de) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die stabilisierte Statin-Partikel enthält
CN100429202C (zh) * 2006-06-30 2008-10-29 浙江新东港药业股份有限公司 一种无定形氟伐他汀钠的制备方法
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
JP2010520273A (ja) * 2007-03-02 2010-06-10 ドン・ア・ファーム・カンパニー・リミテッド ピロリルヘプタン酸誘導体の新規な結晶形態
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
EP2075246A1 (de) 2007-12-27 2009-07-01 M. J. Institute of Research Verfahren zur Herstellung einer amorphen Form von Atorvastatin-Hemicalcium-Salz
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
JP5414884B2 (ja) * 2009-03-30 2014-02-12 ボエグリ − グラビュル ソシエテ アノニム 硬質材料をコーティングした物体の表面をレーザーによって構造化する方法及び装置
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
US9951009B2 (en) * 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
CN106432033B (zh) * 2016-10-21 2018-07-27 江苏阿尔法药业有限公司 一种无定形阿托伐他汀钙的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
ATE123020T1 (de) * 1990-05-11 1995-06-15 American Cyanamid Co N-acylierte arylpyrrole als insektizide, akarizide, nematizide und molluskizide wirkstoffe.
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
GEP20002029B (en) 1995-07-17 2000-04-10 Warner Lambert Company Us (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina

Also Published As

Publication number Publication date
YU36802A (sh) 2005-09-19
JP5087193B2 (ja) 2012-11-28
DE60012045T2 (de) 2005-07-07
US6891047B2 (en) 2005-05-10
DE60012045D1 (de) 2004-08-12
RU2247113C2 (ru) 2005-02-27
PT1237864E (pt) 2004-11-30
SK287032B6 (sk) 2009-10-07
CA2392025C (en) 2009-06-02
PL356184A1 (en) 2004-06-14
KR100729689B1 (ko) 2007-06-18
HRP20020482B1 (en) 2007-05-31
EP1237864A1 (de) 2002-09-11
US6613916B2 (en) 2003-09-02
ES2223615T3 (es) 2005-03-01
TR200402543T4 (tr) 2004-12-21
KR20020073137A (ko) 2002-09-19
AU776854B2 (en) 2004-09-23
UA71041C2 (uk) 2004-11-15
RS50307B (sr) 2009-09-08
JP2003516388A (ja) 2003-05-13
WO2001042209A1 (en) 2001-06-14
BG106786A (en) 2003-05-30
HRP20020482A2 (en) 2004-08-31
AU1543801A (en) 2001-06-18
EE05328B1 (et) 2010-08-16
CA2392025A1 (en) 2001-06-14
BG65719B1 (bg) 2009-08-31
CZ301627B6 (cs) 2010-05-05
EP1237864B1 (de) 2004-07-07
US20020183527A1 (en) 2002-12-05
US20040024046A1 (en) 2004-02-05
PL208226B1 (pl) 2011-04-29
SK7832002A3 (en) 2002-11-06
SI20425A (sl) 2001-06-30
EE200200293A (et) 2003-06-16

Similar Documents

Publication Publication Date Title
ATE270661T1 (de) Verfahren zur herstellung von amorphem atorvastatin
DE69611999D1 (de) Verfahren zur herstellung von amorphem [r-(r*,r*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenyl-amino)carbonyl]-1h-pyrrol-1-heptansäure-calciumsalz (2:1)
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
ATE478079T1 (de) Verfahren zur herstellung der form v von atorvastatin und phenylboronate als zwischenprodukte
HUP9900678A2 (hu) [R-(R*,R*)]-2(4-fluor-fenil)-béta,delta-dihidroxi-5-(1-metil-etil)-3-fenil-4-[(fenil-amino)-karbonil]-1H-pirrol-1-heptánsav-hemikalciumsó (atorvasztatin) kristályos formái, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
IL158790A0 (en) Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
IL155890A0 (en) HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
BG108518A (en) Crystalline forms vi and vii of atorvastatin calcium
IL173651A0 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
DE69616358D1 (de) Kristalline form iii des hemi calcium salzes von [r-(r*,r*)]-2-(4-fluorphenyl)-beta-delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure (atorvastatin)
CA2522899A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
ECSP961822A (es) NUEVO PROCESO PARA LA PRODUCCION DE UNA SAL ACIDA CALCICA AMORFA [R- (R*, R*)]-2-(4- FLUOROFENILO)-ß, 6- DIHIDROXI- 5 - (1- METILETILO)- 3 - FENILO -4-[(FENILAMINO) CARBONILO] - 1H- PIRROL - 1 - ACIDO HEPTANOICO
TH76289A (th) กระบวนการผลิตอะทอร์วาสเตตินแคลเซียมในรูปแบบอสัณฐาน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1237864

Country of ref document: EP